466 related articles for article (PubMed ID: 15003450)
1. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase.
Garman SC; Garboczi DN
J Mol Biol; 2004 Mar; 337(2):319-35. PubMed ID: 15003450
[TBL] [Abstract][Full Text] [Related]
2. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele.
Yasuda M; Shabbeer J; Benson SD; Maire I; Burnett RM; Desnick RJ
Hum Mutat; 2003 Dec; 22(6):486-92. PubMed ID: 14635108
[TBL] [Abstract][Full Text] [Related]
3. [alpha-Galactosidase gene mutation and its expression product in Fabry disease (alpha-galactosidase deficiency)].
Okumiya T; Takata T; Sasaki M; Sakuraba H
Rinsho Byori; 1997 Feb; 45(2):127-35. PubMed ID: 9120996
[TBL] [Abstract][Full Text] [Related]
4. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes.
Ashton-Prolla P; Tong B; Shabbeer J; Astrin KH; Eng CM; Desnick RJ
J Investig Med; 2000 Jul; 48(4):227-35. PubMed ID: 10916280
[TBL] [Abstract][Full Text] [Related]
5. [Fabry disease (alpha-galactosidase deficiency)].
Okumiya T; Sakuraba H
Nihon Rinsho; 1995 Dec; 53(12):2952-9. PubMed ID: 8577042
[TBL] [Abstract][Full Text] [Related]
6. Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography.
Shabbeer J; Robinson M; Desnick RJ
Hum Mutat; 2005 Mar; 25(3):299-305. PubMed ID: 15712228
[TBL] [Abstract][Full Text] [Related]
7. A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted.
Miyamura N; Araki E; Matsuda K; Yoshimura R; Furukawa N; Tsuruzoe K; Shirotani T; Kishikawa H; Yamaguchi K; Shichiri M
J Clin Invest; 1996 Oct; 98(8):1809-17. PubMed ID: 8878432
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of Fabry disease.
Garman SC; Garboczi DN
Mol Genet Metab; 2002; 77(1-2):3-11. PubMed ID: 12359124
[TBL] [Abstract][Full Text] [Related]
9. Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches.
Germain DP; Poenaru L
Biochem Biophys Res Commun; 1999 Apr; 257(3):708-13. PubMed ID: 10208848
[TBL] [Abstract][Full Text] [Related]
10. A missense mutation, A156T, in the alpha-galactosidase A gene causes typical Fabry disease.
Konoshita T; Mutoh H; Yokoi T; Koni I; Miyamori I; Mabuchi H
Clin Nephrol; 2001 Mar; 55(3):243-7. PubMed ID: 11316246
[TBL] [Abstract][Full Text] [Related]
11. Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease.
Okumiya T; Ishii S; Takenaka T; Kase R; Kamei S; Sakuraba H; Suzuki Y
Biochem Biophys Res Commun; 1995 Sep; 214(3):1219-24. PubMed ID: 7575533
[TBL] [Abstract][Full Text] [Related]
12. Two novel alpha-galactosidase A mutations causing Fabry disease: A missense mutation M11V in a heterozygote woman and a nonsense mutation R190X in a hemizygote man.
Celtikci B; Topçu M; Ozkara HA
Clin Biochem; 2011 Jul; 44(10-11):809-12. PubMed ID: 21569769
[TBL] [Abstract][Full Text] [Related]
13. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma.
Froissart R; Guffon N; Vanier MT; Desnick RJ; Maire I
Mol Genet Metab; 2003 Nov; 80(3):307-14. PubMed ID: 14680977
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene.
Eng CM; Desnick RJ
Hum Mutat; 1994; 3(2):103-11. PubMed ID: 7911050
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease: molecular genetics of the inherited nephropathy.
Desnick RJ; Astrin KH; Bishop DF
Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
[TBL] [Abstract][Full Text] [Related]
17. [Molecular genetics of inherited metabolic diseases--its application to the investigation of pathogenesis and the diagnosis of Fabry disease].
Sakuraba H
Rinsho Byori; 1994 Jun; 42(6):628-35. PubMed ID: 7914243
[TBL] [Abstract][Full Text] [Related]
18. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.
Fan JQ; Ishii S; Asano N; Suzuki Y
Nat Med; 1999 Jan; 5(1):112-5. PubMed ID: 9883849
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel point mutation (S65T) in alpha-galactosidase A gene in Chinese patients with Fabry disease. Mutations in brief no. 169. Online.
Chen CH; Shyu PW; Wu SJ; Sheu SS; Desnick RJ; Hsiao KJ
Hum Mutat; 1998; 11(4):328-30. PubMed ID: 9554750
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of alpha-galactosidase from Trichoderma reesei and its complex with galactose: implications for catalytic mechanism.
Golubev AM; Nagem RA; Brandão Neto JR; Neustroev KN; Eneyskaya EV; Kulminskaya AA; Shabalin KA; Savel'ev AN; Polikarpov I
J Mol Biol; 2004 May; 339(2):413-22. PubMed ID: 15136043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
